Lymphoma

Overview of nodular sclerosis Hodgkin lymphoma, including diagnosis, staging, treatment options by stage and possible side effects.

FDA removal of an exclusion allows Yescarta use in primary CNS lymphoma, showing safety and strong efficacy in relapsed disease.

In an interview with CURE, Dr. Lakshmi Nayak explains how an FDA label update expands Yescarta access for relapsed or refractory primary CNS lymphoma.

Gratitude didn’t erase my fear, but it gave me something solid to stand on. It became the coping strategy I needed.

FDA accepted a new drug application for tirabrutinib in relapsed or refractory PCNSL.

Five years ago, I finished treatment and was determined to be no evidence of disease. Until my most recent CT scan, there’s been no sign of recurrence.

Six-time cancer survivor encourages patients to trust doctors, lean on support, and save energy for moving forward instead of fear.

Riozzi Bodine shares how her daughter’s diagnosis inspired the launch of a foundation offering cold caps, wigs and caregiver support.

Most people think of anniversaries as happy things. But there are other anniversaries that commemorate less pleasant events. Some anniversaries are a mix of pleasant and unpleasant.

Hodgkin lymphoma is a cancer of the lymphatic system, which includes lymph nodes, the spleen and immune cells that help the body fight infection.

FDA expands access to CAR-T cell therapy for patients with relapsed or refractory PCNSL.

Former U.S. goalkeeper opens up about a large B-cell lymphoma diagnosis and finally reaching remission after chimeric antigen receptor T cell therapy, urging patients to advocate and seek options.

Losing my cat after years alongside my cancer journey reminded me how much his presence eased stress, anxiety and treatment days.

An expert explains FDA-approved Lymphir for relapsed or refractory CTCL, noting 36% response rate, manageable side effects and fast relief from itching.

Kim Johnson shares her experience losing her sister to cancer, offering guidance for those grieving and for the people supporting them.

The FDA granted orphan drug designation to CTD402 for relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.

After five years in remission, a scan shows a small anomaly that might be recurrence, or it can show nothing, leaving a tense week before my oncologist visit.

Outpatient CD19 CAR-NK plus rituximab led to complete remissions up to 15 months in patients with Waldenström Non-Hodgkin lymphoma.

I have lived with both depression and cancer and know that illness, visible or not, ebbs and flows; canceled plans can reflect health limits, not rejection

Patients with relapsed/refractory diffuse large B-cell lymphoma who received Epkinly alone experienced an improvement in progression-free survival.

Now that I have been living with my chronic cancer for 16 and a half years, I’ve been reflecting on how my attitude has changed over time.

Dr. Ian Flinn explains how Lunsumio VELO works, offering an outpatient immunotherapy option with accelerated FDA approval.

Adding Monjuvi and Revlimid to standard chemotherapy helped patients with newly diagnosed lymphoma live longer without disease worsening.

I reflect on caregiving, loss and gratitude, honoring the people who supported me through my sister’s cancer and my first Thanksgiving without her.

It’s been two-and-a-half years since I “rang the bell” on the Oncology ward, signaling that I had ended my chemotherapy treatment.